IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease

Trends in Immunology

Volumn 32, Issue 5, 2011, Pages 232-239

  Zepp, Jarod ^a,b   Wu, Ling ^a,c   Li, Xiaoxia ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; UBIQUITIN PROTEIN LIGASE E3;

ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNE DISEASE; CYTOKINE PRODUCTION; DEMYELINATING DISEASE; GENE EXPRESSION; HUMAN; IMMUNOPATHOGENESIS; MULTIPLE SCLEROSIS; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TH17 CELL;

ANIMALS; AUTOIMMUNE DISEASES; DEMYELINATING DISEASES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MICE; MULTIPLE SCLEROSIS; RECEPTORS, INTERLEUKIN-17; SIGNAL TRANSDUCTION; TH17 CELLS; TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PEPTIDES AND PROTEINS;

EID: 79955636935     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2011.02.007     Document Type: Review

References (91)

1. Rizzi M., et al. Disruption of immunological tolerance: role of AIRE gene in autoimmunity. Autoimmun. Rev. 2006, 5:145-147.
2. Carson M.J., et al. CNS immune privilege: hiding in plain sight. Immunol. Rev. 2006, 213:48-65.
3. Cassan C., Liblau R.S. Immune tolerance and control of CNS autoimmunity: from animal models to MS patients. J. Neurochem. 2007, 100:883-892.
4. Pagan A.J., et al. T cell-mediated activation and regulation of anti-chromatin B cells. Autoimmun. Rev. 2006, 5:373-376.
5. Rudensky A.Y., et al. FOXP3 and NFAT: partners in tolerance. Cell 2006, 126:253-256.
6. Gauld S.B., et al. Silencing of autoreactive B cells by anergy: a fresh perspective. Curr. Opin. Immunol. 2006, 18:292-297.
7. Brink R. Regulation of B cell self-tolerance by BAFF. Semin. Immunol. 2006, 18:276-283.
8. Cose S. T-cell migration: a naive paradigm?. Immunology 2007, 120:1-7.
9. Cua D.J., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748.
10. Langrish C.L., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 2005, 201:233-240.
11. Murphy C.A., et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 2003, 198:1951-1957.
12. Harrington L.E., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 2005, 6:1123-1132.
13. Park H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 2005, 6:1133-1141.
14. Bettelli E., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
15. Nakae S., et al. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 2002, 17:375-387.
16. Iwakura Y., Ishigame H. The IL-23/IL-17 axis in inflammation. J. Clin. Invest. 2006, 116:1218-1222.
17. Kolls J.K., Linden A. Interleukin-17 family members and inflammation. Immunity 2004, 21:467-476.
18. Weaver C.T., et al. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006, 24:677-688.
19. Harrington L.E., et al. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr. Opin. Immunol. 2006, 18:349-356.
20. Mangan P.R., et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006, 441:231-234.
21. Veldhoen M., et al. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24:179-189.
22. Nurieva R., et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007, 448:480-483.
23. Caruso R., et al. Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat. Med. 2009, 15:1013-1015.
24. Ma H.L., et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J. Clin. Invest. 2008, 118:597-607.
25. Zheng Y., et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007, 445:648-651.
26. Tzartos J.S., et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 2008, 172:146-155.
27. Schulz S.M., et al. IL-17A is produced by Th17, gammadelta T cells and other CD4- lymphocytes during infection with Salmonella enterica serovar Enteritidis and has a mild effect in bacterial clearance. Int. Immunol. 2008, 20:1129-1138.
28. Passos S.T., et al. IL-6 promotes NK cell production of IL-17 during toxoplasmosis. J. Immunol. 2010, 184:1776-1783.
29. Matusevicius D., et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult. Scler. 1999, 5:101-104.
30. Hemdan N.Y., et al. Interleukin-17-producing T helper cells in autoimmunity. Autoimmun. Rev. 2010, 9:785-792.
31. Ye P., et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J. Exp. Med. 2001, 194:519-527.
32. Conti H.R., et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J. Exp. Med. 2009, 206:299-311.
33. Ho A.W., Gaffen S.L. IL-17RC: a partner in IL-17 signaling and beyond. Semin. Immunopathol. 2010, 32:33-42.
34. Ho A.W., et al. IL-17RC is required for immune signaling via an extended SEF/IL-17R signaling domain in the cytoplasmic tail. J. Immunol. 2010, 185:1063-1070.
35. Gonzalez-Garcia I., et al. IL-17 signaling-independent central nervous system autoimmunity is negatively regulated by TGF-beta. J. Immunol. 2009, 182:2665-2671.
36. Hu Y., et al. IL-17RC is required for IL-17A- and IL-17F-dependent signaling and the pathogenesis of experimental autoimmune encephalomyelitis. J. Immunol. 2010, 184:4307-4316.
37. Kawaguchi M., et al. Identification of a novel cytokine, ML-1, and its expression in subjects with asthma. J. Immunol. 2001, 167:4430-4435.
38. Gaffen S.L. An overview of IL-17 function and signaling. Cytokine 2008, 43:402-407.
39. Ruddy M.J., et al. Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members. J. Biol. Chem. 2004, 279:2559-2567.
40. Ely L.K., et al. Structural basis of receptor sharing by interleukin 17 cytokines. Nat. Immunol. 2009, 10:1245-1251.
41. Novatchkova M., et al. The STIR-domain superfamily in signal transduction, development and immunity. Trends Biochem. Sci. 2003, 28:226-229.
42. Li X., et al. Act1, an NF-kappa B-activating protein. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:10489-10493.
43. Qian Y., et al. Role of NF kappa B activator Act1 in CD40-mediated signaling in epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:9386-9391.
44. Leonardi A., et al. CIKS, a connection to Ikappa B kinase and stress-activated protein kinase. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:10494-10499.
45. Chang S.H., et al. Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. J. Biol. Chem. 2006, 281:35603-35607.
46. Qian Y., et al. The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nat. Immunol. 2007, 8:247-256.
47. Liu C., et al. Act1, a U-box E3 ubiquitin ligase for IL-17 signaling. Sci. Signal. 2009, 2:ra63.
48. Huang F., et al. Requirement for both JAK-mediated PI3K signaling and ACT1/TRAF6/TAK1-dependent NF-kappaB activation by IL-17A in enhancing cytokine expression in human airway epithelial cells. J. Immunol. 2007, 179:6504-6513.
49. Saleh A., et al. Critical role for STAT3 in IL-17A-mediated CCL11 expression in human airway smooth muscle cells. J. Immunol. 2009, 182:3357-3365.
50. Hartupee J., et al. IL-17 enhances chemokine gene expression through mRNA stabilization. J. Immunol. 2007, 179:4135-4141.
51. Hartupee J., et al. IL-17 signaling for mRNA stabilization does not require TNF receptor-associated factor 6. J. Immunol. 2009, 182:1660-1666.
52. Zhu S., et al. Modulation of experimental autoimmune encephalomyelitis through TRAF3-mediated suppression of interleukin 17 receptor signaling. J. Exp. Med. 2010, 207:2647-2662.
53. Shen F., et al. IL-17 receptor signaling inhibits C/EBPbeta by sequential phosphorylation of the regulatory 2 domain. Sci. Signal. 2009, 2:ra8.
54. Stromnes I.M., Goverman J.M. Active induction of experimental allergic encephalomyelitis. Nat. Protoc. 2006, 1:1810-1819.
55. Becher B., et al. Antigen presentation in autoimmunity and CNS inflammation: how T lymphocytes recognize the brain. J. Mol. Med. 2006, 84:532-543.
56. Gold R., et al. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006, 129:1953-1971.
57. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005, 23:683-747.
58. McFarland H.F., Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 2007, 8:913-919.
59. Steinman L. Multiple sclerosis: a two-stage disease. Nat. Immunol. 2001, 2:762-764.
60. Agrawal A., et al. ERK1-/- mice exhibit Th1 cell polarization and increased susceptibility to experimental autoimmune encephalomyelitis. J. Immunol. 2006, 176:5788-5796.
61. Bettelli E., et al. Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis. J. Exp. Med. 2004, 200:79-87.
62. Korn T., et al. IL-17 and Th17 Cells. Annu. Rev. Immunol. 2009, 27:485-517.
63. Yang Y., et al. T-bet is essential for encephalitogenicity of both Th1 and Th17 cells. J. Exp. Med. 2009, 206:1549-1564.
64. Lees J.R., et al. Regional CNS responses to IFN-gamma determine lesion localization patterns during EAE pathogenesis. J. Exp. Med. 2008, 205:2633-2642.
65. Segal B.M. Th17 cells in autoimmune demyelinating disease. Semin. Immunopathol. 2010, 32:71-77.
66. Kroenke M.A., et al. IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J. Exp. Med. 2008, 205:1535-1541.
67. Goverman J. Autoimmune T cell responses in the central nervous system. Nat. Rev. Immunol. 2009, 9:393-407.
68. Kleinschek M.A., et al. IL-25 regulates Th17 function in autoimmune inflammation. J. Exp. Med. 2007, 204:161-170.
69. Das M.P., et al. Autopathogenic T helper cell type 1 (Th1) and protective Th2 clones differ in their recognition of the autoantigenic peptide of myelin proteolipid protein. J. Exp. Med. 1997, 186:867-876.
70. Jager A., et al. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J. Immunol. 2009, 183:7169-7177.
71. Steinman L. A rush to judgment on Th17. J. Exp. Med. 2008, 205:1517-1522.
72. Axtell R.C., et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat. Med. 2010, 16:406-412.
73. Komiyama Y., et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 2006, 177:566-573.
74. Ransohoff R.M. Immunology: in the beginning. Nature 2009, 462:41-42.
75. Reboldi A., et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat. Immunol. 2009, 10:514-523.
76. Kebir H., et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med. 2007, 13:1173-1175.
77. Kang Z., et al. Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis. Immunity 2010, 32:414-425.
78. Aloisi F. Immune function of microglia. Glia 2001, 36:165-179.
79. Carson M.J. Microglia as liaisons between the immune and central nervous systems: functional implications for multiple sclerosis. Glia 2002, 40:218-231.
80. Ma X., et al. IL-17 enhancement of the IL-6 signaling cascade in astrocytes. J. Immunol. 2010, 184:4898-4906.
81. Wujek J.R., et al. Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. J. Neuropathol. Exp. Neurol. 2002, 61:23-32.
82. Paintlia M.K., et al. Synergistic activity of interleukin-17 and tumor necrosis factor-alpha enhances oxidative stress-mediated oligodendrocyte apoptosis. J. Neurochem. 2011, 116:508-521.
83. Wang D.D., et al. IL-17 potentiates neuronal injury induced by oxygen-glucose deprivation and affects neuronal IL-17 receptor expression. J. Neuroimmunol. 2009, 212:17-25.
84. Siffrin V., et al. In vivo imaging of partially reversible th17 cell-induced neuronal dysfunction in the course of encephalomyelitis. Immunity 2010, 33:424-436.
85. Swaidani S., et al. The critical role of epithelial-derived Act1 in IL-17- and IL-25-mediated pulmonary inflammation. J. Immunol. 2009, 182:1631-1640.
86. Claudio E., et al. The adaptor protein CIKS/Act1 is essential for IL-25-mediated allergic airway inflammation. J. Immunol. 2009, 182:1617-1630.
87. Qian Y., et al. Deficiency of Act1, a critical modulator of B cell function, leads to development of Sjogren's syndrome. Eur. J. Immunol. 2008, 38:2219-2228.
88. Matsushima Y., et al. An atopic dermatitis-like skin disease with hyper-IgE-emia develops in mice carrying a spontaneous recessive point mutation in the Traf3ip2 (Act1/CIKS) gene. J. Immunol. 2010, 185:2340-2349.
89. Ellinghaus E., et al. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat. Genet. 2010, 42:991-995.
90. Huffmeier U., et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat. Genet. 2010, 42:996-999.
91. Strange A., et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat. Genet. 2010, 42:985-990.